about
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsPhase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)TRAIL in cancer therapy: present and future challenges.Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancerMechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expressionDevelopment of an Fn14 agonistic antibody as an anti-tumor agent.Molecular targeted approaches for treatment of pancreatic cancer.Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal modelTRAIL-receptor antibodies as a potential cancer treatment.Monoclonal antibodies in the treatment of pancreatic cancer.Death receptors as targets for anti-cancer therapy.TRAIL receptor signaling and therapeutics.Combined modality therapy with TRAIL or agonistic death receptor antibodies.Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
P2860
Q27649718-56490EC4-B52D-4916-8CF5-D64383BD56EEQ28391040-CE883814-F03F-43AB-ACEE-C0FC6333038DQ33906524-D60B3271-D4B2-4090-AD0E-9100CB0EA08EQ34291312-64D88BAA-68D6-4300-BDDD-4B2F9F8BDDEEQ34610496-A8EE0DE2-BF4A-4BFD-8560-A8D89EE2E370Q34912378-24066D54-8393-46E7-AB18-17620B211FC1Q35534458-F22D88D5-C336-402A-8755-D89BEB639E71Q35556794-591B8232-D231-440E-AE15-0E0B5FE9904EQ36174910-D88CFD3D-08A6-4C62-B188-8C6EB022E7B2Q36576268-24AF3C57-0389-4DB1-AF47-286D1BD5AFB1Q36895805-19FBF269-1092-40BE-B964-188421AFF12CQ37355568-C1642E8A-2F48-40F0-BAF4-DD4FD47727D3Q37390893-0F59B3B9-4C88-460E-B00E-4FCD814BBD2AQ37785559-B74E23CF-8DEA-4951-A9FF-63A8071ADEA2Q37832083-9701F49A-F444-448E-9ABA-35B7861776CAQ39753915-CEA2ECCC-7237-4A50-8099-1EA10A7F7632
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
TRAIL receptor-targeted therapy.
@ast
TRAIL receptor-targeted therapy.
@en
type
label
TRAIL receptor-targeted therapy.
@ast
TRAIL receptor-targeted therapy.
@en
prefLabel
TRAIL receptor-targeted therapy.
@ast
TRAIL receptor-targeted therapy.
@en
P2860
P356
P1433
P1476
TRAIL receptor-targeted therapy
@en
P2093
Albert F Lobuglio
P2860
P304
P356
10.2217/14796694.2.4.493
P407
P577
2006-08-01T00:00:00Z